Overview

Exploratory Study of Breast Cancer With ABY025

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Biomedical Radiation Sciences

Collaborator:

Swedish Cancer Society